로그인 회원가입
icon_bulk_order대량 주문 Acrobiosystems for English
0
장바구니가 비어 있습니다
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: > GPRC5D

GPRC5D

요약

Name:G-protein coupled receptor family C group 5member D
Target Synonym:G Protein-Coupled Receptor Class C Group 5 Member D,G-Protein Coupled Receptor Family C Group 5 Member D,G Protein-Coupled Receptor, Class C, Group 5, Member D,G Protein-Coupled Receptor, Family C, Group 5, Member D,GPRC5D,Orphan G-Protein Coupled Receptor
Number of Launched Drugs:1
Number of Drugs in Clinical Trials:28
Lastest Research Phase:Approved

Antibody Licensing

Project Name Project Stage Molecule Type Host Species Therapeutic Area Indications
GPRC5D VHH - 01 PCC Hematological Malignancy Multiple myeloma

제품 리스트 구매

일부의 생물활성 데이터

CCHO-STP078-Cell-based assay
 GPRC5D FACS

FACS Analysis of CHO/Human GPRC5D Stable Cell Line.

FACS assay shows that Anti-GPRC5D antibody can bind to CHO/Human GPRC5D Stable Cell Line (Fig. B), and non-transfected CHO cells were used as a negative control (Fig. A). PE signal was used to evaluate the binding activity (QC tested).

GPD-H52D5-SPR
 GPRC5D SPR

Anti-GPRC5D Antibody, Human IgG4 captured on Protein A Chip can bind Human GPRC5D Full Length Protein, Flag,His Tag (Cat. No. GPD-H52D5) with an affinity constant of 57.7 nM as determined in a SPR assay (in presence of DDM and CHS) (Biacore 8K) (Routinely tested).

GPD-C52D3-SPR
 GPRC5D SPR

Anti-GPRC5D Antibody immobilized on CM5 Chip can bind Cynomolgus GPRC5D, Flag,His Tag (Cat. No. GPD-C52D3) with an affinity constant of 0.122 μM as determined in a SPR assay (Biacore T200) (QC tested).

Synonym Name

GPRC5D

Background

G-protein coupled receptor family C group 5 member D (GPRC5D) is a retinoic acid-inducible 40 kDa protein with seven transmembrane segments and a short N terminal extracellular region. Widely expressed in the peripheral system. Expression pattern is high in pancreas, medium in kidney, small intestine, spleen and testis, low in lung, colon, leukocyte, prostate and thymus and not detectable in brain, heart, liver, placenta, skeletal muscle and ovary.

Clinical and Translational Updates

공개 약품 정보

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Talquetamab JNJ-7564; JNJ-64407564 Approved Genmab A/S, Johnson & Johnson Innovative Medicine TALVEY United States Multiple Myeloma Janssen Biotech Inc 2023-08-09 Hematologic Neoplasms; Multiple Myeloma Details

임상 약품 정보

Name Research Code Research Phase Company Indications Clinical Trials
Arlocabtagene autoleucel CC-95266; BMS986393; BMS-986393 Phase 3 Clinical Juno Therapeutics Inc Multiple Myeloma Details
LM-305 LM-305 Phase 2 Clinical LaNova Medicines Ltd Multiple Myeloma Details
BCMA/CD19 chimeric antigen receptor (CAR)-modified T cells Therapy(Peking University People's Hospital) Phase 2 Clinical Peking University People'S Hospital Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Myositis; Immunoglobulin G4-Related Disease; Sjogren's Syndrome; Scleroderma, Systemic; Antiphospholipid Syndrome; Lupus Erythematosus, Systemic; Acquired thrombotic thrombocytopenic purpura; Behcet Syndrome Details
BCMA-GPRC5D CAR-T cells Therapy (Shenzhen University General Hospital) Phase 2 Clinical Shenzhen University General Hospital Multiple Myeloma Details
CAR-T Cell Therapy(Shenzhen Geno-Immune Medical Institute) Phase 2 Clinical Shenzhen Geno-Immune Medical Institute, The No.2 Clinical Hospital of the Ministry of Health Plasmacytoma; Multiple Myeloma Details
Anti-GPRC5D CAR-T Cells Therapy (Shanghai YaKe Biotechnology) Phase 2 Clinical Shanghai YaKe Biotechnology Co Ltd Multiple Myeloma Details
IBI-3003 IBI3003; IBI-3003 Phase 2 Clinical Innovent Biologics(Suzhou) Co Ltd Multiple Myeloma Details
BCMA-GPRC5D CAR-T Cells Therapy (Bio-Gene) Phase 2 Clinical Guangzhou Bio-Gene Technology Co Ltd Multiple Myeloma Details
MBS-314 MBS-314 Phase 2 Clinical Beijing Mabworks Biotech Co Ltd Multiple Myeloma Details
CT-071 CT071; CT-071 Phase 2 Clinical CARsgen Therapeutics Holdings Ltd Leukemia, Plasma Cell; Multiple Myeloma Details
Anti-GPRC5D CAR-T Cells Therapy(Institute of Hematology & Blood Diseases Hospital) Phase 2 Clinical Institute Of Hematology & Blood Diseases Hospital Multiple Myeloma Details
Autologous anti-BCMA/GPRC5D CAR-T cell therapy (Shanghai YaKe Biotechnology) Phase 2 Clinical Shanghai YaKe Biotechnology Co Ltd Multiple Myeloma Details
Ori-CAR-017 Ori-CAR-017; OriCAR-017; GPRC5D-CAR-T Phase 2 Clinical OriCell Therapeutics Co Ltd Hemorrhagic Disorders; Hematologic Diseases; Hemostatic Disorders; Paraproteinemias; Immunoproliferative Disorders; Neoplasms; Blood Protein Disorders; Multiple Myeloma; Immune System Diseases; Vascular Diseases; Neoplasms, Plasma Cell; Cardiovascular Diseases; Lymphoproliferative Disorders Details
LBL-034 LBL-034 Phase 2 Clinical Nanjing WeiLibo biological Technology Co Ltd Neoplasms; Multiple Myeloma Details
SAR-446523 SAR-446523 Phase 1 Clinical Sanofi-Aventis Gmbh Bone Marrow Neoplasms; Multiple Myeloma Details
CM-380 CM380; CM-380 Phase 1 Clinical Keymed Biosciences Co Ltd Multiple Myeloma Details
OL-101 OL-101 Phase 1 Clinical Overland Pharmaceuticals (Shanghai) Co Ltd Multiple Myeloma Details
RD-140 RD140 Phase 1 Clinical Nanjing Iaso Biotherapeutics Co Ltd Leukemia, Plasma Cell; Multiple Myeloma Details
Anti-GPRC5D-CD19-CAR-T cell therapy(The Second People Hospital Of Guangdong Province) Phase 1 Clinical The Second People Hospital Of Guangdong Province Multiple Myeloma Details
BCMAxGPRC5D CAR-T therapy (Juno Therapeutics) BMS-986453 Phase 1 Clinical Juno Therapeutics Inc Multiple Myeloma Details
SIM-0500 SIM0500; SIM-0500 Phase 1 Clinical Simcere Pharmaceutical Group Ltd Bone Marrow Neoplasms; Multiple Myeloma Details
QLS-32015 QLS-32015; QLS32015 Phase 1 Clinical Qilu Pharmaceutical Co Ltd Multiple Myeloma Details
Anti-GPRC5D CAR-T Cells Therapy (Guangzhou Bio-Gene Technology Co Ltd) Phase 1 Clinical Guangzhou Bio-Gene Technology Co Ltd Multiple Myeloma Details
OriC-321 OriC-321; Ori-C-321 Phase 1 Clinical Zhejiang University, OriCell Therapeutics Co Ltd Multiple Myeloma Details
CAR-GPRC5D CAR-GPRC5D; RD-118; RD118 Phase 1 Clinical Nanjing Iaso Biotherapeutics Co Ltd Leukemia, Plasma Cell; Multiple Myeloma Details
Forimtamig RG-6234 Phase 1 Clinical F. Hoffmann-La Roche Ltd Multiple Myeloma Details
MCARH-109 Phase 1 Clinical Memorial Sloan Kettering Cancer Center, Juno Therapeutics Inc, Eureka Therapeutics Inc Multiple Myeloma Details
RO-7425781 RO-7425781 Phase 1 Clinical F. Hoffmann-La Roche Ltd Multiple Myeloma Details
Allogeneic Anti-BCMA/GPRC5D Bispecific CAR-NK Cells therapy(Acellytron Therapeutics) ACT-001(Acellytron Therapeutics) Clinical Acellytron Therapeutics Multiple Myeloma Details

This web search service is supported by Google Inc.

totop